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 Activin is an important orchestrator of wound repair, but its potential role in skin carcinogenesis 
has not been addressed. Here we show using different types of genetically modiﬁ ed mice that 
enhanced levels of activin in the skin promote skin tumour formation and their malignant 
progression through induction of a pro-tumourigenic microenvironment. This includes 
accumulation of tumour-promoting Langerhans cells and regulatory T cells in the epidermis. 
Furthermore, activin inhibits proliferation of tumour-suppressive epidermal  γ δ T cells, resulting 
in their progressive loss during tumour promotion. An increase in activin expression was also 
found in human cutaneous basal and squamous cell carcinomas when compared with control 
tissue. These ﬁ ndings highlight the parallels between wound healing and cancer, and suggest 
inhibition of activin action as a promising strategy for the treatment of cancers overexpressing 
this factor.  
 1  Department of Biology, Institute of Cell Biology , ETH  Zurich , 8093 Zurich,  Switzerland .  2  Department of Dermatology, University of Lausanne , 1011 
 Lausanne ,  Switzerland .  3  Department of Immunology and Microbial Science, The Scripps Research Institute ,  La Jolla ,  California 92037,  USA .  4  Department 
of Dermatology, University Hospital , 8091  Zurich ,  Switzerland .  * These authors contributed equally to this work. Correspondence and requests for materials 
should be addressed to S.W. (email:  sabine.werner@cell.biol.ethz.ch ) .  
 Activin enhances skin tumourigenesis and 
malignant progression by inducing a 
pro-tumourigenic immune cell response 
 Maria  Antsiferova 1 ,  Marcel  Huber 2 , * ,  Michael  Meyer 1 , * ,  Aleksandra  Piwko-Czuchra 1 , * ,  Tamara  Ramadan 1 , 
 Amanda S.  MacLeod 3 ,  Wendy L.  Havran 3 ,  Reinhard  Dummer 4 ,  Daniel  Hohl 2  &  Sabine  Werner 1 
ARTICLE
2 
NATURE COMMUNICATIONS  |  DOI:  10.1038/ncomms1585 
NATURE COMMUNICATIONS  | 2:576  |  DOI:  10.1038/ncomms1585  | www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
 There are remarkable similarities between wound healing and cancer 1 , and the presence of a  ‘ wound healing gene expres-sion signature ’ is a hallmark of highly malignant carcinomas 2 . 
Th erefore, it is of particular interest to identify wound-regulated 
genes and to characterize their functions in cancer development and 
progression. Major orchestrators of wound repair are activins, which 
belong to the transforming growth factor (TGF)- β superfamily of 
growth and diff erentiation factors. Th e most abundant activin variant 
is activin A, the homodimer formed by two  β A subunits. Activins 
exert their biological eff ects through activation of transmembrane 
serine / threonine kinase receptors. Binding to a type II activin recep-
tor (ActRII or ActRIIB) leads to the phosphorylation and activation of 
a type I activin receptor (ActRIB, also known as Alk4, ActRIA  =  Alk2 
or ActRIC  =  Alk7). Th is activates the canonical signalling pathway via 
Smad proteins, or, alternatively, mitogen-activated kinase pathways 3 . 
 Activins were initially described as reproductive hormones, but 
they also have important functions in development, tissue homoe-
ostasis and repair 4 . Furthermore, abnormalities in activin receptor 
expression and / or signalling are associated with various human 
diseases, including cancer 5 . 
 We previously showed a strong increase in activin  β A expression 
in healing skin wounds 6 . Th is is functionally relevant, as transgenic 
mice overexpressing the activin antagonist follistatin in keratino-
cytes showed delayed wound repair 7 , whereas overexpression of 
activin  β A in keratinocytes strongly accelerated the healing proc-
ess. However, healed wounds of activin-overexpressing mice had a 
hyperproliferative neo-epidermis (ref.  8 , and M.A. and S.W. unpub-
lished results). Th erefore, we speculated about a role of activin in the 
pathogenesis of skin cancer. 
 Few functional studies have addressed the role of activin in 
malignancy, and pro- or anti-tumourigenic eff ects of activin have 
been reported, depending on the tissue and the type of cancer 9 – 11 . 
Most of these data were obtained with xenograft  models in immuno-
compromised hosts, whereas a potential role of the immunomodu-
latory actions of activin 12 in the pathogenesis of cancer has not been 
addressed. In this study, we identifi ed a novel and unexpected func-
tion of activin in the pathogenesis of non-melanoma skin cancer that 
is mediated through its eff ect on diff erent epidermal immune cells. 
 Results 
 Activin promotes skin tumourigenesis in mice .  To determine a 
potential role of activin in skin carcinogenesis, we used transgenic 
mice expressing activin  β A in keratinocytes under control of the 
keratin 14 (K14) promoter (Act mice) 8 . Th ey secrete high levels 
of activin A, which can act on keratinocytes directly but also on 
stromal cells due to the high diff usibility of activin A 13 . Th is is 
refl ected by the 30-fold increase in activin A levels in skin lysates and 
the 200-fold increase in the serum compared with wild-type (wt) 
animals ( Supplementary Fig. S1 ). Expression of high levels of activin 
A by keratinocytes did not interfere with the growth inhibitory 
eff ect of TGF- β on keratinocytes ( Supplementary Fig. S1 ). Most 
importantly, the back skin of these mice did not reveal any histological 
abnormalities, and keratinocyte proliferation in normal back skin 
epidermis was not aff ected by the enhanced levels of activin 8 . 
 Act mice as well as sex- and age-matched wt littermates were 
subjected to a two-stage chemical skin carcinogenesis protocol, 
where tumours are induced by topical treatment of the back skin 
with 7,12-dimethylbenz[a]anthracene (DMBA), followed by weekly 
treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) 14,15 . 
A remarkable pro-tumourigenic eff ect of activin was observed in three 
independent experiments with mice of diff erent genetic background 
(experiments I – III,  Table 1 ) as refl ected by the earlier appearance of 
papillomas and the strong increase in the percentage of mice with 
tumours (tumour incidence) and in the number of tumours per 
mouse (tumour multiplicity) ( Fig. 1a,b;  Supplementary Fig. S2 ). 
 Table 1  |  Summary of carcinogenesis experiments. 
 Experiment  DMBA (1 × ) (  g)  TPA (20 × ) (  g)  Genotypes  Genetic background  N 
 I  25  5  Wt  CD1  31 
 Act  29 
 II  25  7.5  Wt / wt  CD1xC57BL / 6  17 
 Act / wt  17 
 III  25  7.5  Wt / wt  CD1xB6D2F1  18 
 Act / wt  18 
 Wt / dnActRIB  18 
 Act / dnActRIB  18 
 Control I  25  —  Act  CD1  5 
 Wt  5 
 Control II  —  5  Act  CD1  6 
 Wt  6 
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 Figure 1  |  Activin promotes chemically induced skin tumourigenesis 
in mice via action on stromal cells. ( a , b ) Kinetics of tumour incidence 
( a ) or multiplicity ( b ) observed in experiment I ( Table 1 ).  N  =  31 wild-
type (wt) mice;  N  =  29 activin-transgenic (Act) mice. ( c , d ) Kinetics of 
tumour incidence ( c ) and multiplicity ( d ) in experiment III.  N  =  18 mice per 
genotype. Kaplan – Meier survival curves are shown in ( a ) and ( c ); mean  ±  s.
e.m. are shown in ( b ) and ( d );  * * P  <  0.01,  * * * P  <  0.001 for the comparison 
between wt / wt and Act / wt mice;  # #   P  <  0.01,  # # #   P  <  0.001 for the 
comparison between Act / wt and Act / dnActRIB mice (two-way repeated 
measures ANOVA and Bonferroni post-test). 
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Mice treated only with DMBA or TPA did not develop tumours, 
demonstrating that both a mutagenic insult and a proliferative stim-
ulus are required. Th is is consistent with the fi nding that wounding 
alone did not induce tumourigenesis in control or Act mice (M.A. 
and S.W., unpublished results). 
 Activin induces skin carcinogenesis via the stroma .  To determine 
if activin stimulates skin tumourigenesis through autocrine activa-
tion of keratinocytes and / or through paracrine / endocrine activa-
tion of stromal (mesenchymal or immune) cells, we used transgenic 
mice expressing a dominant-negative mutant of ActRIB (Alk4) in 
keratinocytes under control of the K14 promoter (dnActRIB mice) 
and mated them with Act mice. dnActRIB lacks the complete intra-
cellular kinase domain, and through formation of non-functional 
heterodimers with type II activin receptors it effi  ciently blocks 
activin but not TGF- β signalling 16 . Th is approach was chosen, as 
keratinocytes express multiple activin receptors 6 , which are all 
inhibited by dnActRIB. Th e dnActRIB mice have no obvious phe-
notypic abnormalities under non-challenged conditions 16 , and the 
dnActRIB transgene neither aff ected expression of the activin  β A 
transgene nor the bioavailability of the recombinant activin A (data 
not shown and  Supplementary Fig. S1 ). Th erefore, in Act / dnActRIB 
mice, the highly diff usible, recombinant activin can activate all cells 
in the skin, but its eff ect on keratinocytes is antagonized by dnAc-
tRIB expressed by these cells. Th e functionality of dnActRIB in the 
double-transgenic mice had previously been demonstrated 16 and 
was further verifi ed by analysis of S100A8 and S100A9 expression. 
Th us, we had previously shown a strongly increased expression of 
these cytokines in the hyperthickened tail epidermis of Act mice 17 . 
We verifi ed this increase with new mice (250-fold) and found that 
it was almost completely suppressed (  >  90 % ) in Act / dnActRIB mice 
(data not shown). 
 We performed a two-stage chemical skin carcinogenesis study 
with the F1 progeny of dnActRIB and Act mice (experiment III, 
 Table 1 ). Th e latency period and tumour incidence of the activin-
overexpressing mice were not aff ected by dnActRIB ( Fig. 1c ), but 
the tumour multiplicity was signifi cantly increased in the double-
transgenic mice as compared with Act single-transgenic animals 
( Fig. 1d ). Th is fi nding points to the existence of a tumour-inhibitory 
eff ect of activin A, which is mediated via keratinocytes and there-
fore aff ected by dnActRIB and which depends on the presence of 
high levels of activin. However, the potent pro-tumourigenic eff ect 
seems to be predominantly mediated via the stroma. 
 Activin promotes tumour malignancy .  Th e vast majority of 
the tumours collected 20 weeks aft er initiation were papillomas 
( Fig. 2a ). Th ere was no diff erence in tumour cell proliferation and 
apoptosis between genotypes ( Supplementary Fig. S2 and data not 
shown), but several tumours in activin-overexpressing mice already 
contained sites of high-grade dysplasia and foci of microinvasion 
( Fig. 2a ; arrow). Twelve weeks aft er termination of TPA treatment, 
the percentage of papillomas that progressed to malignancy was 
slightly increased in activin-overexpressing compared with wt and 
dnActRIB mice. Most importantly, the percentage of mice with 
malignant tumours was signifi cantly higher in the groups of animals 
expressing the activin transgene ( Fig. 2b ). 
K14/VimentinH/E
Actwt
H/EH/E K14
Genotype Percentage of papillomas that
progress to malignancy a
Percentage of mice with
malignant tumours b
wt/wt 2.8 (1/36) 9.1 (1/11)
wt/dnActRIB 3.6 (2/55) 9.1(1/11)
Act/wt 7.1 (11/155) 63.6 (7/11)*
Act/dnActRIB 7.6 (19/251) 70.0 (7/10)**
 Figure 2  |  Activin increases malignancy and metastatic spread of skin tumours. ( a ) Hematoxylin / eosin (H / E)-stained sections from papillomas 20 
weeks after initiation. Local micro-invasive foci (arrow) were often observed in papillomas of Act mice (lower panel). Bars: 1,000  μ m (top), 100  μ m 
(bottom). Areas indicated by the box on the top pictures are shown at higher magniﬁ cation on the bottom pictures. ( b ) Malignant conversion rate of 
tumours 32 weeks after initiation (experiment III).  a ()  =  number of carcinomas / total number of tumours.  b ()  =  number of mice with carcinomas / total 
number of mice.  N  =  10 Act / dnActRIB mice,  N  =  11 wt / wt, Act / wt, wt / dnActRIB mice;  * P  =  0.0237 for Act / wt versus wt / wt,  * * P  =  0.0075 for Act /
 dnActRIB versus wt / wt (Fisher ’ s exact test). ( c ) H / E staining (left) and double immunoﬂ uorescence for keratin (K)14 and vimentin (right) of a spindle cell 
variant of squamous cell carcinoma (SCC) in an Act mouse. Left bar: 1,000  μ m; right bar: 200  μ m. The area indicated by a box on the left picture is shown 
at higher magniﬁ cation on the right picture. ( d ) Lung (top panel) and lymph node (bottom panel) metastases in carcinoma-bearing Act mice. Left and 
middle: H / E staining; right: K14 immunohistochemistry. Left bar: 1,000  μ m; middle and right bars: 200  μ m. 
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 Histopathological analysis and immunostaining for keratins 14, 
6, 10 and 13 revealed that most of the malignant tumours were squa-
mous cell carcinomas (SCCs) . Five out of 11 malignant tumours in 
Act / wt mice and 1 out of 19 in Act / dnActRIB mice had spindle-
shaped tumour cells, showed vimentin immunoreactivity ( Fig. 2c ), 
and are likely to be a spindle cell variant of SCCs 18 . 
 Four out of 9 activin-overexpressing mice with malignant tumours 
developed lung metastases ( Fig. 2d ), whereas this was not observed in 
wt mice. In experiment II, we collected inguinal and axillary lymph 
nodes 32 weeks aft er DMBA initiation. K14-positive metastatic nod-
ules were observed in 3 out of 3 carcinoma-bearing Act-transgenic 
mice ( Fig. 2d ) and in 1 out of 2 wt mice with carcinomas. 
 Th ese results suggest that activin A not only accelerates tumouri-
genesis but also malignant progression of papillomas. 
 Activin does not aff ect DMBA or TPA responsiveness .  To gain 
insight into the mechanisms underlying the enhanced tumourigen-
esis in Act mice, we analysed the skin before and following short-
term treatment with DMBA and TPA. Consistent with the lack of 
obvious histological abnormalities in the back skin 8 , proliferation of 
keratinocytes and epidermal thickness were not altered in untreated 
Act mice ( Fig. 3a,b ). Several pro-infl ammatory cytokines and chem-
okines were normally expressed ( Supplementary Fig. S2 ), and there 
was no infl ammatory infi ltrate in the skin (data not shown). 
 We also could not detect alterations in the expression of several 
DMBA metabolizing or detoxifying enzymes, or in the proliferation 
rate of keratinocytes 24  h aft er DMBA treatment in Act versus wt 
mice ( Supplementary Fig. S2 ). 
 One day aft er the fi rst TPA treatment, we found a minor increase 
in keratinocyte proliferation and a slightly thicker epidermis in Act 
and Act / dnActRIB mice compared with control mice ( Fig. 3a,b; 
 Supplementary Fig. S2 ). Th e diff erence in keratinocyte proliferation 
remained non-signifi cant at later stages of TPA treatment ( Supple-
mentary Fig. S2 ), but the diff erence in epidermal thickness increased 
continuously ( Fig. 3c ). 
 Th e TPA-induced infl ammatory response was not obviously 
altered by activin overexpression as determined by fl ow cytom-
etry analysis of dermal single-cell suspensions (CD45   +   leucocytes, 
Gr1   +   CD11b   +   and Gr1   −   CD11b   +   myeloid cells, CD3   +   T cells and 
F4 / 80   +   macrophages) ( Supplementary Fig. S3 ). Furthermore, sev-
eral pro-infl ammatory cytokines and chemokines were expressed 
at similar levels in TPA-treated skin of wt and Act mice ( Fig. 3d ). 
Th e only diff erence was the increased expression of S100A8 and 
A9 in Act mice, which most likely refl ects an altered activation /
 diff erentiation state of the keratinocytes 17 . Several growth factors 
known to be induced by TPA and to contribute to TPA-induced 
tumour promotion 19 – 21 were expressed at similar levels in control 
and Act mice ( Fig. 3d ). In particular, expression of TGF- β 1,  β 2 and 
 β 3 was not altered, suggesting that the observed phenotype is not 
due to diff erences in TGF- β expression ( Fig. 3d ). 
 Finally, the number of blood vessels and the area of dermis cov-
ered by blood vessels 1d aft er the fi rst TPA application as well as in 
papillomas collected aft er 20 TPA applications were similar in wt 
and Act mice ( Supplementary Fig. S3 ). Consistently, the expression 
levels of various angiogenesis-regulating factors were not altered by 
activin overexpression ( Supplementary Fig. S2 and S3 ). 
 Loss of epidermal  γ δ T cells in TPA-treated Act mice .  Diff er-
ent subsets of T cells are either tumour-promotive or tumour-
suppressive 22,23 . Dendritic epidermal T cells (DETCs) represent a 
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 Figure 3  |  Activin overexpression does not affect DMBA or TPA responsiveness. ( a ) Epidermal BrdU   +   cells per mm of basement membrane (BM) in 
untreated back skin or 1 day after the ﬁ rst TPA treatment. Scatter plot and mean values are shown;  N  =  5 – 8 mice per group;  n  =  6 – 23 microscopic ﬁ elds 
of skin sections per mouse. ( b ) Epidermal thickness in untreated mice or 1 day after the ﬁ rst TPA treatment.  N  =  3 – 4;  n  =  6 – 13;  * P ≤ 0.05,  * * P ≤ 0.01 (one-
way ANOVA with Bonferroni post-test). ( c ) Epidermal thickness 7 days after the third TPA treatment or 3 days after the eighth TPA treatment.  N  =  6 – 7; 
 n  =  3 – 30;  * * P  =  0.0047 for 3 × TPA,  * * P  =  0.0012 for 8 × TPA (Mann – Whitney test). ( d ) RNA samples from back skin 1 day after the ﬁ rst TPA treatment 
were analysed for expression of pro-inﬂ ammatory cytokines and growth factors by quantitative reverse transcription PCR.  N  =  5 – 10 mice per genotype. 
 Rps29 was used as reference. Box-and-whisker plot is depicted, with boxes showing median and 25th and 75th percentile, whiskers showing minimal and 
maximal values.  * * P  =  0.0047 for  S100a8 ,  * * P  =  0.0027 for  S100a9 (Mann – Whitney test). 
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subpopulation of unconventional, resident T cells expressing the  γ δ 
T-cell receptor (TcR) 24 . Remarkably, they kill skin-derived tumour 
cells  in vitro and protect against diff erent types of experimental skin 
tumours  in vivo , including DMBA / TPA-induced papillomas and 
SCCs 25,26 . Immunofl uorescence staining with pan- γ δ TcR antibod-
ies revealed a severe depletion of  γ δ T cells in the non-tumourigenic 
epidermis of activin-overexpressing mice aft er 20 TPA applications 
( Fig. 4a,b ), but not in untreated skin ( Fig. 4c ). Loss of these cells 
was dependent on TPA but not on DMBA ( Supplementary Fig. S4 ). 
A time course analysis revealed a continuous reduction in the 
number of epidermal but not of dermal  γ δ T cells in Act mice upon 
repeated TPA treatment ( Fig. 4d ;  Supplementary Fig. S4 ). 
 Epidermal  γ δ T cells uniformly express a TcR encoded by 
the  V γ 3 gene segment 27 and display a characteristic dendritic 
morphology, whereas systemic  γ δ T cells in the lymphoid organs 
and lungs express the V γ 2 TcR 28 . Most of the  γ δ T cells remaining in 
Act animals aft er chronic TPA treatment lacked dendrites and had 
a lower TcR δ staining intensity ( Fig. 4a,e;  Supplementary Fig. S4 ). 
Immunofl uorescence staining revealed that four out of six activin-
overexpressing mice completely lacked V γ 3   +   DETCs in the epider-
mis aft er eight TPA applications ( Fig. 4e ). At this stage, only 14.9 % 
of the remaining  γ δ T cells in the epidermis of Act mice, but   >  99 % 
of these cells in wt mice were V γ 3 positive ( Fig. 4e,f ). Similar results 
were obtained for non-tumourigenic skin collected aft er 20 TPA 
applications, where V γ 3   +   cells comprised   >  99 % of all  γ δ T cells in 
wt mice versus 25 % in Act mice. At the same time, a minor increase 
in V γ 2   +   cells was observed in the epidermis of TPA-treated wt and 
Act animals ( Supplementary Fig. S4 ), whereas V γ 2   +   cells were not 
found in the untreated epidermis of mice from both genotypes. 
 Twelve weeks aft er termination of TPA application the number 
of TcR δ   +   cells remained very low in Act mice ( Supplementary Fig. 
S4 ). As precursors of  γ δ T cells are only present during embryonic 
development and can only populate the skin shortly aft er birth 29 , 
the depletion of DETCs is irreversible and the phenotype cannot be 
rescued by adoptive transfer of these cells. 
 Epidermal  γ δ T cells express activin receptors .  Depletion of  γ δ 
T cells also occurred in Act / dnActRIB mice, suggesting that the 
eff ect is not mediated via keratinocytes ( Supplementary Fig. S4 ). 
To determine if activin can directly aff ect epidermal  γ δ T cells, we 
fi rst analysed the expression of activin receptors by DETCs using 
RNA of fl uorescence-activated cell (FACS)-sorted CD3   +   TcR δ   +  
cells from untreated epidermis of wt mice. Th e CD3   −   TcR δ   −   popu-
lation, consisting predominantly of keratinocytes and Langerhans 
cells, was used for comparison. DETCs expressed  Acvr1, Acvr1c as 
well as  Acvr2a and  Acvr2b ( Fig. 5a ). Although we cannot exclude 
that the signal partially results from a minor contamination of the 
CD3   +   TcR δ   +   fraction with K14-positive cells ( Fig. 5a ), the simi-
lar expression levels of most activin receptors in both populations 
strongly suggest that they are indeed expressed by DETCs. 
 Activin inhibits  γ δ T cell proliferation .  We next determined the 
reason underlying the loss of DETCs upon TPA treatment. Although 
the K14 promoter is active in thymic epithelial cells 30 , the number 
of the foetal thymic precursors of DETCs was not obviously aff ected 
in Act mice ( Supplementary Fig. S5 ), and developmental abnor-
malities are therefore unlikely. Th is is also refl ected by the normal 
number and morphology of DETCs in untreated skin of Act mice 
( Fig. 4c ). 
 Furthermore, loss of DETCs did not result from their emigration 
to the draining lymph nodes induced by stressed keratinocytes 31 , 
as the number of TcR δ   +   cells present in the skin-draining lymph 
nodes of TPA-treated skin was similar in wt and transgenic mice 
( Supplementary Fig. S5 ). 
 Apoptosis of DETC was excluded by staining of sections from 
TPA-treated skin for cleaved caspase-3 or by TUNEL.  In vitro , addi-
tion of 12.5 or 50  ng  ml   −  1 activin A to resting or stimulated DETC 
7-17 cells or freshly isolated epidermal  γ δ T cells did not aff ect their 
survival as assessed by fl ow cytometry analysis of 7-AAD exclusion 
or by annexin V / propidium iodide staining (data not shown). 
 Finally, we determined if activin aff ects proliferation of DETCs 
using Ki67 immunofl uorescence staining of skin sections prepared 
7 days aft er the fi rst TPA or 1 day aft er the second TPA application. 
In all, 20 % of the TcR δ   +   cells in the epidermis of wt mice, but only 
3.5 % in Act mice expressed Ki67 ( Fig. 5b,c ). To verify this fi nding, 
we labelled proliferating cells  in vivo with 5-ethynyl-2 ′ -deoxyu-
ridine (EdU), and subsequently analysed the percentage of EdU-
positive TcR δ   +   cells using fl ow cytometry. Whereas  γ δ T cell prolif-
eration was similar in untreated skin of mice from both genotypes, 
proliferation of DETCs increased in response to TPA in wt mice, but 
not in Act or Act / dnActRIB mice ( Fig. 5d – f ). 
 Analysis of the DETC growth and survival factors interleukin 
(IL)-7 and IL-15 32,33 revealed that activin did not aff ect IL-15 
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TPA application.  N  =  5 – 11;  n  =  9 – 33;  * * P  =  0.0011 for DMBA  +  2 × TPA  +  1d, 
 * * P  =  0.0025 for DMBA  +  8 × TPA  +  3d (Mann – Whitney test). Scatter plot 
and mean values are shown in ( b ), ( c ) and ( d ). ( e ) Sections from back 
skin of wt and Act mice 3 days after the eighth TPA application were co-
stained with antibodies against the pan- γ δ TcR (TcR δ ) and the V γ 3 variant 
of  γ δ TcR. Nuclei were counterstained with Hoechst. Arrows indicate 
TcR δ   +   cells. Representative micrographs are shown in ( a ) and ( e ). Arrows 
indicate TcR δ   +   cells. Bar: 50  μ m. Dotted lines indicate dermal / epidermal 
border. ( f ) Epidermal TcR δ   +   cells and V γ 3   +   cells per mm of BM. Bar graph 
shows the mean number of TcR δ   +   cells per mm of BM, numbers above 
the columns indicate the corresponding percentage of V γ 3   +   cells among 
TcR δ   +   cells.  N  =  7;  n  =  3 – 13. 
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expression. However, IL-7 mRNA levels were reduced by  ~ 50 % in 
non-treated skin and aft er the second TPA application in Act and 
Act / dnActRIB animals ( Fig. 5g,h ). In addition, activin directly 
reduced the proliferation rate of primary DETCs in the presence of 
suboptimal concentrations of anti-CD3 antibodies ( Fig. 5i ). Th ere-
fore, activin seems to suppress DETC proliferation through direct 
and indirect mechanisms during chronic TPA treatment when these 
cells have to be amplifi ed to maintain an appropriate number in the 
hyperproliferative epidermis, which has a high turnover. 
 Activin increases epidermal    T cells and Langerhans cells . 
 Th e loss of  γ δ T cells phenocopies the situation seen in  γ δ T-cell-
defi cient mice and thus provides a likely mechanistic explanation 
for the enhanced carcinogenesis in activin-overexpressing mice. 
To determine if additional types of immune cells can further enhance 
the pro-tumourigenic eff ect of activins, we fi rst analysed  α β T cells 
that promoted malignant conversion in the model of chemically 
induced skin carcinogenesis 26 . 
 Th ere was no signifi cant diff erence in the number of  α β T cells in 
the dermis of TPA-treated skin ( Supplementary Fig. S5 ). However, the 
number of  α β T cells infi ltrating the epidermis during DMBA / TPA-
induced tumourigenesis was signifi cantly higher in activin-overexpress-
ing mice ( Fig. 6a,b ). Th us, lack of  γ δ T cells is likely to act in concert with 
the accumulation of  α β T cells in the promotion of carcinogenesis. 
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Bonferroni post-test). ( g , h ) RNA samples from trypsin-separated epidermis from untreated mice ( g ) or from mice after the second TPA application ( h ) 
were analysed for expression of  Il15 and  Il7 by quantitative reverse transcription PCR using  Rps29 or  Gapdh as reference. Expression in one of the wt mice 
was arbitrarily set to 1.  N  =  4 – 5;  * * * P ≤ 0.001 (one-way ANOVA with Bonferroni post-test). Scatter plot and mean values are shown in ( c ), ( e ), ( f ), ( g ) and 
( h ). ( i ) V γ 3   +   Thy1.2   +   cells were FACS sorted and cultured for 48  h with immobilized anti-CD3 antibodies (0.1  μ g  ml   −  1 ) in the absence (ctrl) or presence of 
50  ng  ml   −  1 activin A (Act).  3 H-thymidine incorporation assay was performed in quadruplicates. Data are representative of two independent experiments; 
mean values  ±  s.d. are shown;  * P  =  0.0286 (Mann – Whitney test). 
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 Characterization of the subpopulations of  α β T cells revealed 
that the number of epidermal CD8   +   cells was only slightly 
increased in transgenic animals, whereas signifi cantly more CD4   +  
cells had infi ltrated the epidermis of Act mice aft er eight TPA treat-
ments ( Fig. 6c,d ). Staining with an antibody against the regulatory 
T cell (Treg) marker Foxp3 revealed a signifi cant increase in these 
immunosuppressive cells in the epidermis of Act animals aft er 
chronic TPA treatment ( Fig. 6e,f ), but not in the dermis ( Supple-
mentary Fig. S5 ). 
 We found a signifi cant increase in the number of Langerhans 
cells in DMBA / TPA-treated Act mice ( Fig. 6g,h ). Th e percentage 
of langerin-positive cells that also expressed the activation marker 
CD86 was similar in wt and Act mice, suggesting that activation of 
Langerhans cells is not obviously impaired ( Supplementary Fig. S6 ). 
As Langerhans cells promote DMBA / TPA-induced skin carcinogen-
esis 34 , they are likely to further contribute to the pro-tumourigenic 
phenotype in Act mice. 
 Taken together, our results demonstrate that activin induces a 
pro-tumourigenic immune cell response, which involves diff erent 
types of epidermal T cells and Langerhans cells. 
 Activin is overexpressed in human skin carcinomas .  Finally, we 
addressed the role of endogenous activin in skin carcinogenesis in 
mice and humans. Consistent with a role of endogenous activin in 
skin carcinogenesis,  activin   A ( Inhba ) mRNA levels were slightly 
upregulated aft er short-term TPA treatment and were almost 100-
fold increased in the papillomas of wt mice compared with untreated 
skin ( Supplementary Fig. S7 ). Most importantly, we found a strong 
increase in the levels of  activin   A mRNA in human basal cell car-
cinomas (BCC) and even more in SCC samples as compared with 
normal skin ( Fig. 7a ), whereas follistatin RNA levels were similar 
in normal and tumourigenic skin ( Fig. 7b ). Immunohistochemical 
staining of sections from human SCCs with an activin A-specifi c 
antibody revealed that activin is expressed by keratinocytes of the 
tumour as well as in the adjacent epidermis ( Fig. 7c – e ). Epidermal 
staining was also seen in normal skin ( Fig. 7f ). In addition, stain-
ing was observed in blood vessels of normal skin and in particular 
in the enlarged tumour vessels ( Fig. 7d,e ). Th is fi nding refl ects the 
importance of our data for human skin carcinogenesis. 
 Discussion 
 In this study, we provide a new molecular link between wound 
healing and cancer: Th e major orchestrator of wound repair, the 
growth and diff erentiation factor activin, was identifi ed as a potent 
pro-tumourigenic factor in the skin. Remarkably, blocking activin 
receptor signalling in keratinocytes revealed that the pro-tumouri-
genic eff ect is predominantly mediated via the stroma. Th is was 
further supported by the similar proliferation rate of keratinocytes 
in wt and Act mice  in vivo and in vitro (M.A., M.M. and S.W unpub-
lished results). 
 Although activin can have both pro- and anti-infl ammatory 
properties 4 , we did not fi nd signifi cant alterations in various infl am-
matory parameters in normal or DMBA / TPA-treated back skin of 
activin-transgenic mice. Similarly, activin demonstrated pro- 35 or 
anti-angiogenic 36 properties in diff erent systems. However, our 
results suggest that the pro-tumourigenic function of activin in the 
skin does not result from its eff ect on angiogenesis. 
 By contrast, activin strongly aff ected cells involved in tumour 
immunosurveillance. In particular, DETCs were depleted in TPA-
treated skin of Act mice. As these cells have a tumour-suppressive 
function 25,26 , their loss is likely to result in reduced clearance of 
stressed / transformed keratinocytes and a subsequent increase in 
tumour formation as demonstrated previously for  γ δ T-cell-defi cient 
mice 25 and here for our activin-transgenic animals. As the under-
lying mechanism, we identifi ed a potent growth inhibitory eff ect 
of activin for DETCs. Th e results obtained with double-transgenic 
mice suggest that this phenomenon is not mediated via activin-
induced alterations of keratinocytes, but rather involves a direct 
action of activin on DETCs or is mediated via other stromal cells. 
Th e fi rst hypothesis is supported by the expression of activin recep-
tors by DETCs  in vivo and the inhibition of primary epidermal  γ δ 
T-cell proliferation by activin  in vitro . Growth inhibition of DETCs 
is likely to be further enhanced  in vivo through reduced expression 
of IL-7 in Act mice. As IL-7 functions as a homoeostatic signal, 
preventing atrophy and sustaining the basal rate of metabolism in 
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 Figure 6  |  Accumulation of    T cells and Langerhans cells in the 
epidermis of activin-overexpressing mice. ( a , b ) Sections from back skin 
at different time points of TPA treatment stained with TcR β antibodies. 
( a ) Arrows indicate TcR β   +   cells. ( b ) TcR β   +   cells per mm of basement 
membrane (BM).  N  =  4 – 11 mice per group;  n  =  3 – 25 microscopic ﬁ elds 
of skin sections per mouse;  * P  =  0.0159;  * * P  =  0.0022 (Mann – Whitney 
test). ( c , d ) Sections from back skin after eight TPA applications stained 
with antibodies against CD8, CD4 and TcR β . ( c ) Arrows and arrowheads 
indicate CD8   +   or CD4   +   cells, respectively. ( d ) Different subpopulations of 
T cells per mm of BM.  N  =  6 – 7;  n  =  4 – 24; mean values are shown;  * P  =  0.01 
for comparison of TcR β   +   CD4   +   cells between wt and Act mice (Mann –
 Whitney test). ( e , f ) Sections from back skin after eight TPA applications 
stained with Foxp3 antibodies. ( e ) Arrows indicate Foxp3   +   cells. ( f ) 
Epidermal Foxp3   +   cells per mm of BM.  N  =  7;  n  =  6 – 25;  * * * P  =  0.0006 
(Mann – Whitney test). ( g , h ) Sections from back skin after 20 TPA 
applications stained with langerin antibodies. ( g ) Arrows indicate langerin   +   
cells. ( h ) Langerin   +   cells per mm of BM.  N  =  7 – 10;  n  =  3 – 25;  * * P  =  0.0012 
(Mann – Whitney test). Representative sections are shown in ( a ), ( c ), ( e ) 
and ( g ), and the dermal – epidermal border is indicated by dotted lines. 
Nuclei were counterstained with Hoechst ( a ), ( c ), and ( e ) or propidium 
iodide ( g ). Bars: 25  μ m. Scatter plots and mean values are shown in ( b ), ( f ) 
and ( h ). 
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T cells 37 , its reduction in activin-overexpressing mice could result 
in a dampened metabolic rate of DETCs, inhibiting proliferation 
aft er chronic stimulation by TPA. 
 Apart from targeting the tumours directly, DETCs were also sug-
gested to reduce the potential of  α β T cells to promote tumourigen-
esis 38 . Th erefore, lack of  γ δ T cells is likely to act in concert with 
the accumulation of  α β T cells in the promotion of carcinogenesis. 
Th e increase in epidermal  α β T cells also provides a likely explana-
tion for the enhanced malignant progression of existing tumours, as 
these cells also promoted tumour progression in TcR δ   −  /  −   mice 26 . 
 Consistent with the recently identifi ed role of activin in induction 
of Tregs 39,40 , we found a signifi cant accumulation of Foxp3   +   cells in 
the epidermis of TPA-treated activin-overexpressing mice. Interest-
ingly, Foxp3   +   cells also infi ltrate human SCCs and are thought to at 
least in part mediate the evasion of the immune response by these 
tumours 41 . 
 Finally, we found a signifi cant increase in the number of Langer-
hans cells in TPA-treated skin of activin-overexpressing mice. Th is 
fi nding is consistent with the reduction in the number of Langer-
hans cells in follistatin-overexpressing mice 42 and with the activin 
A-induced Langerhans cell diff erentiation  in vitro and in human 
skin samples 43 . As Langerhans cells promote DMBA / TPA-induced 
skin carcinogenesis 34 , they are likely to further contribute to the 
pro-tumourigenic phenotype in Act mice. In the future, it will be 
interesting to determine if there is a possible contribution of these 
and additional immune cells in the response to activin. Interesting 
candidates are macrophages that diff erentiate towards the immuno-
suppressive and tumour-promotive M2 phenotype in response to 
activin 44 , as well as dendritic cells and natural killer cells that are 
functionally aff ected by activin 45,46 . 
 Th e functional data obtained with our mouse models are likely to 
be important for the human situation, as we found a strong increase 
in activin A expression in human BCCs and in particular in SCCs. In 
the future, it will be important to determine if the enhanced expres-
sion of activin seen in these tumours correlates with abnormalities 
in the T-cell repertoire in the aff ected patients. Although epidermal 
 γ δ T cells are much more abundant in murine skin compared with 
human skin, they contribute to effi  cient wound repair in humans 47 . 
In some patients, the percentage of  γ δ T cells among epidermal 
T cells can be up to 20 % . In addition, functional fi ndings for murine 
epidermal T cells have also been applicable for human epidermal-
resident T cells 47,48 . Th erefore, they may well contribute to skin 
carcinogenesis, an issue that should be explored in the future. Such 
studies will also reveal if enhanced expression of activin aff ects anti-
tumour immunity in humans, resulting in more malignant tumours 
and metastatic spread. Th e recently observed upregulation of activin 
expression in keratinocytes of human oral SCCs and the correlation 
of activin overexpression with poor prognosis strongly support this 
hypothesis 49 . Th us, targeting of activin or its downstream mediators 
may emerge as a novel approach for the treatment of carcinomas 
that overexpress this factor. As activin antagonists were recently 
shown to reverse cancer cachexia and muscle wasting 50 and cancer-
induced bone destruction 51,52 in animal models, it may well be that 
targeting activin action could inhibit tumour growth and progres-
sion, and at the same time prevent cancer-induced morbidity. 
 Methods 
 Animal experiments .  Mice were housed under optimal hygiene conditions and 
maintained according to Swiss animal protection guidelines. All procedures with 
mice were approved by the local veterinary authorities of Zurich or Lausanne, 
Switzerland. 
 Genotyping of genetically modifi ed mice is described in the  Supplementary 
Methods . 
 For chemical skin carcinogenesis, 25  μ g of  DMBA ( Sigma ) dissolved in acetone 
was applied on the back skin of 8 – 10-week-old female mice 2 days aft er shaving. 
One week later, 5  μ g (CD1 background) or 7.5  μ g (mixed background) of  TPA 
( Sigma ) in acetone was applied weekly for 20 weeks. We used a higher dosage 
of TPA for the animals of a mixed genetic background, as the parental strains 
of dnActRIB mice (C57BL / 6 and DBA / 2) are relatively resistant to chemically 
induced skin carcinogenesis 53 . A summary of all carcinogenesis experiments 
with the concentrations of DMBA and TPA used is presented in  Table 1 . Tumour 
number and size were documented bi-weekly. Aft er 20 weeks of TPA treatment, 
half of the animals of each genotype were killed. Biopsies of non-tumourigenic 
back skin and all tumours with at least 2  mm diameter were used for histology, 
immunohistochemistry or RNA isolation. 
 TPA treatment was stopped aft er 20 weeks and tumour observation was 
continued until the mice started to develop ulcerated tumours (30 – 40 weeks aft er 
initiation). All large and / or ulcerated tumours were collected for histopathological 
analysis by three independent investigators with expertize in cutaneous histopa-
thology. 
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 Figure 7  |  Activin is overexpressed in human skin carcinomas. ( a ) RNA samples from normal human skin, basal cell carcinomas (BCCs) and SCCs were 
analysed for expression of activin  β A ( INHBA ) by quantitative reverse transcription PCR. Hypoxanthine-guanine phosphoribosyl-transferase  (HPRT) 
was used as a reference. Expression levels in one of the normal skin samples were set to 1. Closed and open squares represent values from normal skin 
collected from the edge of tumours or from healthy adult volunteers, respectively.  N  =  7 normal skin samples;  N  =  7 BCC samples;  N  =  11 SCC samples; 
 * P  =  0.0111,  * * P  =  0.0038 (Mann – Whitney test). ( b ) RNA samples from normal human skin and SCCs were analysed for expression of follistatin (FST) 
by quantitative reverse transcription PCR.  HPRT was used as a reference.  N  =  4 normal skin samples;  N  =  7 SCC samples. Scatter plot and median values 
are shown in ( a ) and ( b ). ( c – f ) Sections of human SCCs ( c – e ) and normal skin ( f ) were stained with an activin A antibody and counterstained with 
hematoxylin. The areas indicated by the box in ( c ) and ( d ) are shown at high magniﬁ cation in ( d ) and ( e ), respectively. Note the expression of activin in 
the tumour cells and in blood vessels. Bar: 500  μ m ( c ), 100  μ m ( d ) or 50  μ m ( e , f ). 
ARTICLE 
9
NATURE COMMUNICATIONS  |  DOI:  10.1038/ncomms1585 
NATURE COMMUNICATIONS  | 2:576  |  DOI:  10.1038/ncomms1585  | www.nature.com/naturecommunications
© 2011 Macmillan Publishers Limited. All rights reserved.
 Lungs and lymph nodes were embedded in paraffi  n, and every 7 – 10th section 
was stained with hematoxylin / eosin (H / E) and examined for the presence of 
metastatic nodules. 
 Immunoﬂ uorescence and immunohistochemical analysis .  For preparation of 
frozen sections, tissue samples were immediately frozen in  tissue freezing medium 
( Leica Microsystems ). For preparation of paraffi  n sections, they were either fi xed in 
95 % ethanol / 1 % acetic acid or in 4 % paraformaldehyde. 
 Cryosections (4 or 7  μ m) were fi xed with ice-cold methanol for 10  min. Paraffi  n 
sections were deparaffi  nized through incubation in xylene and subsequently in a 
graded series of ethanol. Sections were then blocked with 3 % bovine serum albu-
min (BSA) and incubated with the primary antibody, followed by a fl uorochrome-
labelled secondary antibody. For immunohistochemistry, sections were incubated 
with biotinylated secondary antibodies and developed using the  Vectastain ABC kit 
and  3-amino-9-ethylcarbazole ( AEC ) or  3,3 ′ -diaminobenzidine ( DAB )  peroxidase 
substrate kits ( Vector Laboratories ). Th e antibodies used are listed in  Supplemen-
tary Table S1 . 
 For activin A immunohistochemistry, formalin-fi xed paraffi  n sections were 
deparaffi  nized and incubated for 45  min at 98  ° C in 0.5  M ethylenediaminetetraacetic 
acid pH 8 in a water bath for antigen retrieval. Endogenous peroxidase activity 
was blocked by incubation in 3 – 4 % H 2 O 2 , while unspecifi c binding sites were 
blocked by a 1-h incubation at room temperature in 12 % BSA, 0.1 % Tween 20, 
0.1 % NP40 in phosphate-buff ered saline. Subsequently, the sections were incubated 
overnight at 4  ° C with the primary antibody, followed by a 1-h incubation at room 
temperature with a horse radish peroxidase (HRP)-conjugated secondary antibody. 
Th e anti-rabbit poly-HRP-IgG polymer from the  Bond Polymer Refi ne Detec-
tion System ( Leica Microsystems ) was used for enhancement of the signal. Th e 
substrate chromogen, DAB, was used for detection of the complex. Sections were 
counterstained with hematoxylin. 
 Stained sections were photographed using an  Imager.A1 microscope equipped 
with an  Axiocam Mrm camera and  enhanced-contrast Plan-Neofl uor objectives 
(10 × / 0.3 NA, 20 × / 0.5 NA; all from  Carl Zeiss, Inc .).  Axiovision 4.6 soft ware ( Carl 
Zeiss, Inc ) was used for data acquisition. 
 BrdU incorporation assay .  Mice were injected intraperitoneally with 250  mg  kg   −  1 
BrdU 2  h before killing. Samples were fi xed in 95 % ethanol / 1 % acetic acid, and 
embedded in paraffi  n. BrdU-positive cells were detected with a  horseradish peroxi-
dase-conjugated monoclonal antibody against BrdU ( Roche ), and visualized with 
0.05 % DAB / 0.005 % H 2 O 2 . Counterstaining was performed with H / E. 
 TUNEL assay .  Apoptosis on tissue sections was analysed using the  In situ Cell 
Death Detection Kit ( Roche ) according to the manufacturer ’ s instructions. 
 RNA isolation and quantitative reverse transcription PCR .  Total RNA was 
isolated using the  RNeasy Fibrous Tissue Mini Kit or the  RNeasy Midi Kit ( Qiagen ) 
according to the manufacturer ’ s instructions, including a  DNase treatment step 
( Promega ). cDNA was synthesized using the  iScript kit ( Bio-Rad Laboratories ). 
Relative gene expression was determined using the  Roche LightCycler 480 SYBR 
Green system ( Roche ). Th e gene-specifi c primers used are listed in  Supplementary 
Table S2 . 
 Isolation of cells for ﬂ ow cytometry .  Single-cell suspensions of epidermal cells 
were prepared as described previously 54 . Disaggregated epidermal cells were 
fi ltered through a 70- μ m  nylon cell strainer ( BD Pharmingen ), centrifuged at 
1,200  rpm at 4  ° C for 10  min and resuspended in FACS buff er (phosphate-buff ered 
saline, 0.2 % BSA and 5  mM ethylenediaminetetraacetic acid). 
 Dermis was cut into small pieces, and incubated for 45  min at 37  ° C under 
continuous shaking in DMEM containing 2.5  mg  ml   −  1  collagenase II ( Worthing-
ton ), 2.5  mg  ml   −  1  collagenase IV ( Invitrogen ), 0.5  mg  ml   −  1 DNase I and 1  mg  ml   −  1 
 hyaluronidase ( Worthington ). Th ymi were mechanically disaggregated and fi ltered 
through a 70- μ m nylon cell strainer. Lymph nodes were incubated for 30  min at 
37  ° C under continuous shaking in DMEM containing 5  mg  ml   −  1 of  collagenase IV 
( Invitrogen ). Disaggregated dermal cells were treated as described for epidermal 
cells. 
 Flow cytometry .  Cells were incubated for 10  min at 4  ° C with  rat anti-mouse 
CD16 / CD32 monoclonal antibody ( clone 2.4G2 ,  BD Biosciences ) to prevent 
non-specifi c antibody binding, followed by a 30-min incubation at 4  ° C with 
directly labelled specifi c antibodies ( Supplementary Table S3 ). Aft er washing with 
FACS buff er,  7-AAD ( BD Biosciences ) was added to discriminate between viable 
and dead cells. Data acquisition was performed using a FACS Calibur equipped 
with  CellQuestPro soft ware ( BD Biosciences ) and analysis was done using  FlowJo 
soft ware ( Tree Star Inc. ). 
 FACS sorting and reverse transcription PCR .  Epidermal cells were isolated, 
stained with antibodies as described above, and FACS sorted using a  FACS Aria 
Cell Sorter ( BD Biosciences ). RNA was isolated from the sorted cells using the 
 RNeasy Micro Kit ( Qiagen ), and cDNA was generated using the  High-Capacity 
cDNA Reverse Transcription Kit ( Applied Biosystems ) according to the manufac-
turers ’ instructions. 
 DETC culture .  Th e 7 – 17 DETC line was grown in RPMI 1640 medium supple-
mented with 10 % FCS, 25  mM HEPES, 100  U penicillin  100  μ g   −  1 streptomycin, 
2  mM glutamine, 100  μ M non-essential amino acids, 1  mM sodium pyruvate, 
50  μ M 2-mercaptoethanol and 20  U  ml   −  1 of recombinant human IL-2. Cells were 
restimulated every 4 – 5 weeks overnight with 5  μ g  ml   −  1 of concanavalin A and 
were allowed to rest for 2 weeks before use in assays. 
 For isolation of primary DETCs, skin was incubated on 0.3 % trypsin for 
2 – 2.5  h at 37  ° C, and the epidermis was separated from the dermis. Epidermis 
was incubated for 10  min in 0.3 % trypsin at 37  ° C. Th e epidermal preparation was 
enriched for live cells by centrifugation over lympholyte M, and cells recovered 
from the interface were cultured as described above, with the exception that the 
medium contained 10  U  ml   −  1 of IL-2. Survival and proliferation experiments were 
performed with  recombinant activin A ( R & D Systems ). 
 Survival of DETCs was assessed by 7-AAD exclusion or annexin V / propidium 
iodide staining. 
 For proliferation analysis, V γ 3   +   Th y1.2   +   cells were FACS sorted and subse-
quently cultured in the presence of  immobilized anti-CD3 antibodies ( BD Bio-
sciences , clone 500A2, 0.1  μ g  ml   −  1 ), with or without activin A. Th ey were pulsed 
with 0.5  μ Ci  3 H-thymidine, harvested 18  h later onto glass fi bre fi lters, and counts 
were detected in a scintillation counter. 
 EdU incorporation assay .  EdU ( Invitrogen ) was injected intraperitoneally twice 
a day (100  μ g per mouse). Incorporated EdU was analysed in epidermal single-cell 
suspensions by fl ow cytometry using the  Click-iT EdU Flow Cytometry Assay Kit 
( Invitrogen ). Th e  LIVE / DEAD Fixable Dead Cell Stain Kit ( Invitrogen ) was used to 
discriminate between live and dead cells. 
 Human skin biopsies .  Normal human skin and skin cancer samples were obtained 
anonymously from the Departments of Dermatology, University Hospitals of 
Lausanne and Zurich (in the context of the biobank project), approved by the local 
and cantonal Research Ethics Committees. Normal skin was from healthy adult 
volunteers or from the edges of skin tumours. BCC or SCC was diagnosed by ex-
perienced pathologists. Informed consent for research was obtained before routine 
diagnostic services. All samples included the dermis and the epidermis. 
 Statistical analysis .  Statistical analysis was performed using the  GraphPad Prism 
version 5.0 for Mac OS X ( GraphPad Soft ware ). For analysis of tumour incidence, 
comparison of the curves showing the mice with tumours was performed using 
log-rank  χ 2 test. Tumour multiplicity was analysed using two-way repeated meas-
ures analysis of variance (ANOVA). Malignant conversion rate and the percentage 
of mice with malignant tumours were analysed by Fisher ’ s exact test. Mann – 
Whitney test was used for comparing two groups of data; ANOVA test was used for 
comparing three or more groups.  * P ≤ 0.05,  * * P ≤ 0.01 and  * * * P ≤ 0.001. Diff erences 
between groups that were not labelled with asterisks were non-signifi cant.  
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